Phibro Animal Health Corporation (PAHC)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 800 | 833 | 942 | 978 | 1,018 | 1,296 | 1,518 | 1,498 |
| Operating profit | $m | 110 | 198 | ||||||
| Net profit | $m | 34 | 54 | 49 | 33 | 2 | 48 | 100 | 126 |
| EPS reported | $ | 1.19 | 2.44 | ||||||
| Operating cashflow per share | $ | 1.98 | 1.63 | ||||||
| Capex per share | $ | 0.95 | 1.32 | ||||||
| FCF per share | $ | 1.03 | 0.31 | ||||||
| Free cash flow | $m | 42 | 10 | ||||||
| Net debt | $m | 642 | 651 | ||||||
| Book value equity | $m | 286 | 385 | ||||||
| Book value per share | $ | 7.02 | 9.40 | ||||||
| Number of shares | m | 40.7 | 41 | ||||||
| DPS (TTM paid) | $ | 0.48 | 0.48 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 21.46 | 14.79 | ||||||
| P/B LTM | x | 3.62 | 2.68 | ||||||
| P/S LTM | x | 0.80 | 0.68 | ||||||
| P/FCF LTM | x | 24.73 | 104.84 | ||||||
| EV/EBITDA LTM | x | 11.77 | 7.31 | ||||||
| EV/Sales LTM | x | 1.33 | 1.42 | ||||||
| Earnings Yield LTM | % | +4.66% | +6.76% | ||||||
| FCF Yield | % | +4.04% | +0.95% | ||||||
| Quality | |||||||||
| ROE | % | +16.89% | +29.49% | ||||||
| ROIC | % | +7.18% | +11.38% | ||||||
| Operating margin | % | +8.52% | +12.27% | ||||||
| Gross margin | % | +30.85% | +32.49% | ||||||
| FCF/Sales | % | +3.23% | +0.85% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +27.37% | +49.17% | ||||||
| Net Income Growth YoY | % | +1897.7% | +4027.5% | ||||||
| FCF Growth | % | -9.76% | -78.72% | ||||||
| Operating Profit Growth | % | +107.19% | +272.20% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +1.88% | +1.40% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | +40.16% | +20.42% | ||||||
| FCF/Debt | x | 0.05 | 0.01 | ||||||
| Net Debt/EBITDA | x | 4.72 | 3.25 | ||||||
| EBIT/Net interest | x | 3.32 | 4.01 | ||||||
| Net debt/market cap | % | +69.48% | +52.80% | ||||||
| Net debt/Equity | x | 2.25 | 1.69 | ||||||
| Gross debt/equity | x | 2.67 | 2.05 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Phibro Animal Health Corporation (PAHC)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Phibro Animal Health Corporation operates as a global entity focused on the research, production, and supply of a wide array of animal health and mineral nutrition solutions. While serving a global clientele, its primary market for livestock products is the United States. The company's operations are divided into three main business segments: Animal Health, Mineral Nutrition, and Performance Products. Phibro develops, manufactures, and markets products tailored for various food-producing animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its Animal Health offerings encompass a broad range of pharmaceutical and biological products. These include antimicrobials (both chemical and biological agents) designed to prevent and treat bacterial ailments; anticoccidials, primarily used to control and prevent coccidiosis in poultry and cattle; anthelmintics for combating parasitic intestinal worm infestations; and specific anti-bloat treatments for cattle grazing on legume or wheat pastures. Additionally, the company provides specialized nutritional supplements engineered to enhance animal health and performance, alongside vaccines predominantly for the poultry and swine industries to protect against diseases. The Mineral Nutrition segment focuses on the creation and distribution of various trace mineral formulations and concentrates, featuring elements such as zinc, manganese, copper, iron, and other vital compounds. Furthermore, under its Performance Products segment, Phibro supplies an assortment of specialty ingredients that find application in diverse industries, including personal care, industrial chemicals, and chemical catalysts. Phibro's animal health and mineral nutrition products reach customers through a multi-channel distribution network, including its own local sales offices, direct sales to integrated poultry, swine, and cattle operations, and through commercial animal feed producers, wholesalers, and distributors. The company boasts an extensive international presence, conducting business across the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific region. Initially known as Philipp Brothers Chemicals, Inc., the company adopted the name Phibro Animal Health Corporation in July 2003. It was officially incorporated in 2014 and maintains its corporate headquarters in Teaneck, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free